Concentration of B-CG and sFlt-1 in Rattus Norvegicus Model of Preeclampsia with Swimming Exercise Treatment

Preeclampsia (PE) is a life-threatening pregnancy complication for the mother and fetus. High concentrations of human chorionic gonadotrophin (hCG) and soluble fms-like tyrosine kinase-1 (sFLt-1) during pregnancy may have a role in the pathophysiology of PE. Swimming Exercise (SE) is one of the physical activities recommended for pregnant women and carries a minimal risk. This study is aimed at analyzing the interaction between the conditions of rats (normal and PE), the onset of PE (early onset and late onset), and the time of SE (SE 0 minutes; SE 5 minutes; SE 10 minutes) on the concentrations of B-CG and sFlt-1 in the Rattus norvegicus (R. norvegicus) model of PE. 72 R. norvegicus were included in this study and divided into 12 experimental groups (each group n = 6 individuals). R. norvegicus PE was prepared by inducing L-Nitro-Arginine-Methyl Ester (L-NAME) at a 75 mg/kg BW/day dose. The determination of PE was supported by the observation of differences in the values of urine protein (PU), urine glucose (GU), and urine leukocytes (LU) in R. norvegicus before and after injection of L-NAME. The three-factorial statistical test showed a significant interaction between the concentration of B-CG and the condition of R. norvegicus, the onset of PE, and the time of SE, with a p-value <0.001. The three-factorial statistical test also showed a significant interaction between the sFLt-1 concentration and the condition of R. norvegicus, the onset of PE, and the time of SE with p<0.05. The difference in the concentration of B-CG and sFLt-1 R. norvegicus in each treatment group was influenced by the condition of the rats (normal and PE), the onset of PE (early onset and late onset), and the time of SE (SE 0 minutes; SE 5 minutes; SE 10 minutes). Research related to SE on PE still needs to be continued to decide on recommendations on whether SE can be used as a preventive measure in complementary midwifery care for preventing and reducing symptoms of PE in pregnancy. Doi: 10.28991/ESJ-2023-07-03-021 Full Text: PDF